RESEARCH HIGHLIGHT
January 2024

In the latest installment of The Bioverge Podcast, Kiersten Stead from DCVC Bio highlighted Creyon Bio as a prime example of DCVC’s investment philosophy, which centers on deep tech. During the discussion, Kiersten emphasized the crucial role of our purpose-built datasets, computational models, and diverse team of experts.  
 
“It was one of those companies where the founders had an idea, and right away, we realized they had the expertise to execute on that idea,” said Kiersten. 
  
Tune in to the podcast to learn more about Creyon Bio and how we are working to develop oligonucleotide-based medicines for both rare and common diseases and deploy our technology across partnerships.